Clinical efficacy of amrubicin in patients with small cell lung cancer relapse after first-line treatment including immune checkpoint inhibitors: A retrospective multicenter study (TOPGAN 2021-01).

Shinya UematsuSatoru KitazonoHisashi TanakaRyota SaitoYosuke KawashimaFumiyoshi OhyanagiTakehiro TozukaTsugitomi RyosukeToshio SakataniAtsushi HoriikeTakahiro YoshizawaMasafumi SaikiYuichi TamboJunji KoyamaMasaki KanazuKeita KudoYuko Tsuchiya-KawanoNoriko YanagitaniMakoto Nishio

Published in: Thoracic cancer (2022)

Our study suggested that the therapeutic effect of AMR was not enhanced after ICI on SCLC. However, AMR may be effective in cases of sensitive relapse after chemo-ICI. There was no increase in severe toxicity associated with AMR after ICI.

Keyphrases

small cell lung cancer
free survival
photodynamic therapy
oxidative stress
early onset
squamous cell carcinoma
cancer therapy
radiation therapy
drug induced